Immutep Ltd
ASX:IMM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Immutep Ltd
Total Liabilities & Equity
Immutep Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immutep Ltd
ASX:IMM
|
Total Liabilities & Equity
AU$147.2m
|
CAGR 3-Years
20%
|
CAGR 5-Years
14%
|
CAGR 10-Years
12%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Liabilities & Equity
$782.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
0%
|
|
|
CSL Ltd
ASX:CSL
|
Total Liabilities & Equity
$37.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Liabilities & Equity
AU$24.8m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Liabilities & Equity
AU$1.2B
|
CAGR 3-Years
66%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Liabilities & Equity
AU$159.1m
|
CAGR 3-Years
71%
|
CAGR 5-Years
20%
|
CAGR 10-Years
32%
|
|
Immutep Ltd
Glance View
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The firm has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.
See Also
What is Immutep Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
147.2m
AUD
Based on the financial report for Dec 31, 2025, Immutep Ltd's Total Liabilities & Equity amounts to 147.2m AUD.
What is Immutep Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
12%
Over the last year, the Total Liabilities & Equity growth was -19%. The average annual Total Liabilities & Equity growth rates for Immutep Ltd have been 20% over the past three years , 14% over the past five years , and 12% over the past ten years .
